Top Markets
#1 Helium Helium +116.83%
#2 MowCat MowCat +103.58%
#3 Seeker Seeker +97.95%
#4 Pons Pons +54.26%
#5 AI XOVIA AI XOVIA +49.74%
#6 UnifAI Network UnifAI Network +29.60%
#7 Bounce Bounce +27.22%
#8 pipedog pipedog +23.55%
#9 Zylo Ecosystem Zylo Ecosystem +21.30%
#10 TENDIES TENDIES +20.58%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Nxera Pharma Co., Ltd. Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd.

4565
Rank in Stocks #11675
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a... Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Share Price
$7.32
Last synced: 2026-08-28
Market Cap
$671.50M
Change (1 day)
1.08%
Change (1 year)
16.38%
Country
JP
Trade Nxera Pharma Co., Ltd. (4565)

Category

Healthcare
Revenue for Nxera Pharma Co., Ltd. (4565)
Revenue in Aug 2026 TTM: 0
According to Nxera Pharma Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Nxera Pharma Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH